SIGLEC1 and cancer: Based on the results of studies on CD169 macrophage expression conducted directly on tissues of other urological [5] and non-urological cancers [3], we believe that future studies on the expression of this marker in PCa tissues will also demonstrate its usefulness—especially in predicting the risk of lymph node involvement.